Serum-free, xeno-free medium, optimized specifically for activation and expansion of T cells, 500 mL
SKU: 05-080-1A

Availability: In stock




Product Overview:

BIOTARGET™-1 SFM is a serum-free, xeno-free medium developed and optimized specifically for activation and expansion of PBMC - peripheral blood mononuclear cells (lymphocytes and monocytes). This medium is available in many customized packaging configurations, including Sartorius-Stedim cultibags.


  • Xeno-free
  • Chemically defined
  • No added cytokines
  • Comprehensive validation studies
  • CE Mark
  • Manufactured in ISO 13485:2016 and ISO 9001:2008 certified facility


  • Mitogen mediated activation of peripheral blood mononuclear cells (PHA, CON.A, OKT-3)
  • Lymphoid cell mediated activation of mononuclear cells (RAJI, PEER, BA, MOLT-4, JURKAT)
  • IL-2 and IL-3 production from mononuclear cells
  • Long-term post- activation culture of mononuclear cells
  • LAK / TIL cell generation by mononuclear cell interleukin-2 mediated activation
  • Natural killer cell (NK) generation by mononuclear cell activation
  • Cytotoxic T cell generation by mononuclear cell activation
  • Activation of macrophages
  • Investigating various cytokines’ influence on the production of mononuclear cell sub-populations
  • HIV proliferation
  • Retrovirus proliferation in T cells for vaccine development



QTY 500 mL
Glutamine No Glutamine
Storage Conditions 2-8°C
Shipping Conditions Cold Pack



  1. T. Wei et al. Rapid and sensitive detection of microRNA via the capture of fluorescent dyes-loaded albumin nanoparticles around functionalized magnetic beads. Biosensors and Bioelectronics. Volume 94, 15 August 2017, Pages 56-62
  2. V. l. Eisenberg et al. Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor. Frontiers in Immunology, 29 September 2017
  3. S. Janik et al. Diverse Regulation of Vitamin D Receptor Gene Expression by 1,25-Dihydroxyvitamin D and ATRA in Murine and Human Blood Cells at Early Stages of Their Differentiation. International Journal of Molecular Science. 2017, 18(6), 1323
  4. K. Shamalov et al. The mutational status of p53 can influence its recognition by human T-cells. OncoImmunology, Volume 6, 2017 - Issue 4
  5. J. Leonardo et al. A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease. Biochemical Journal, October 2017, Volume: 474 Issue: 20
  6. Y. Gilad et al. Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells. Peptide Science, Volume 106, Issue 2, March 2016, Pages 160–171
  7. R. Meir et al. Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T-Cells in Vivo with Gold Nanoparticles and CT Imaging. ACS Nano, 2015, 9 (6), pp 6363–6372
  8. O. Betzer et al. In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications. Scientific Reports volume 5, Article number: 15400, 2015
  9. Y. Fisher et al. Th1 Polarization of T Cells Injected into the Cerebrospinal Fluid Induces Brain Immunosurveillance. The Journal of Immunology, vol. 192 no. 1 92-102, 2014.
  10. Y. Tal et al. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget, 5(21): 10949–10958, 2014.
  11. Y. Ilan, H.L. Weiner. Combination Therapy of Beta-Glycolipids and Antibodies for the Treatment of Immune-Related Disorders. US 20140255420 A1, 2014.
  12. C. Ankri et-al. Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity. The Journal of Immunology vol. 191 no. 8 4121-4129, 2013.
  13. I. Llaudó et al. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transplant International Volume 26, Issue 2, pages 177–186, February 2013.
  14. Y. Porat. Method for using directing cells for specific stem/progenitor cell activation and differentiation. US 8956870 B2, 2013 .
  1. I. Daniel-Meshulam et al. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. International Journal of Cancer, Volume 133, Issue 12, pages 2903–2913, 2013.
  2. I. Llaudó Vallmajor et al. Impact of small molecules immunosuppressants on P-glycoprotein activity and T-cell function. Journal of Pharmacy and Pharmaceutical Sciences, vol. 15, num. 3, p. 407-419, 2012 .
  3. A. Nemirovski et al. Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology. Journal of Neuroimmunology, Volume 247, Issues 1-2, Pages 95–99, 2012 .
  4. S. Abuybul et al. TGF-β signaling through SMAD2/3 induces the quiescent microglial phenotype within the CNS environment. Glia Volume 60, Issue 7, pages 1160–1171, July 2012.
  5. E. Elinav, N. Adam, T. Waks and Z. Eshhar. Amelioration of Colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 136(5): 1721-1731, 2009.
  6. Yang-Ming Tseng, Sheng-Yi Chen, Chien-Hung Chen, et al.,. Effects of Alcohol-Induced Human Peripheral Blood Mononuclear Cell (PBMC) Pretreated Whey Protein Concentrate (WPC) on Oxidative Damage. Journal of Agricultural and Food Chemistry, 56 (17): 8141–8147, 2008.
  7. Q. Leng, Z. Bentwich and G. Borkow. Increased TGF-ß, Cbl-b and CTLA-4 levels and immunosuppression in association with chronic immune activation. International Immunology 18(5): 637-644, 2006.
  8. D. Melamed, O. Messika, L. Glass-Marmor and A. Miller. Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. International Immunology 18(9):1355-1362, 2006.
  9. C. Rabinowitz and B. Rinkevich. Epithelial cell cultures from Botryllus schlosseri palleal buds: accomplishments and challenges. Methods in Cell Science 25 (3-4), 2004.
  10. F. Martí, E. Bertran, M. Llucià, et al., Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8. Journal of Leukocyte Biology 72: 590-597, 2002.
  11. A. Bishara, R. Malka, C. Brautbar, et al., Cytokine production in human mixed leukocyte reactions performed in serum-free media. Journal of Immunological Methods 215 (1-2): 187-190, 1998.
  12. G. Kampen, L. Poulsen, C. Reimert and P. Skov. A method for production and determination of histamine releasing activity from human peripheral blood mononuclear cell. Journal of Immunological Methods 210(2): 185-193, 1997.
  13. S. Morecki, Y. Gelfand, S. Levi, et al., Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients. Journal of Hematotherapy, 6 (2):115-124, 1997.
  14. Malka R.; Brautbar C.; Kedar E.; et al., Human mixed leukocyte reaction (MLR) performed in serum-free media and serum-containing medium. Human immunology 44(1) : 137, 1995.


Certificate of Analysis

Certificates of Analysis (COA's) describe quality control data for specific product lots.
Please enter the product lot number and click search.
If your search does not return any results, please contact us for assistance.


Write Your Own Review

You're reviewing: BIOTARGET™-1 SFM

How do you rate this product? *

  1 star 2 stars 3 stars 4 stars 5 stars



Use spaces to separate tags. Use single quotes (') for phrases.

You may also be interested in the following product(s)

Pharmacidal™ Sprays and Solution

Pharmacidal™ Sprays and Solution

2 Review(s)

Starting at: $149.00